DUBLIN, Calif. & CHICAGO--(BUSINESS WIRE)--New products in the Essential Line from ZEISS being introduced for U.S. eye care providers include the VISUPHOR® 500 digital phoropter and the VISUSCREEN® 100/ 500 acuity charts for use in subjective refraction; the portable VISUSCOUT® 100 fundus camera for retinal examinations; and the VISUPLAN® 500 non-contact tonometer for intraocular pressure testing. These are added to an already powerful lineup: proven slit lamps with imaging functions and applanation tonometers, as well as products for objective refraction: the VISUREF® 100 autorefractor/keratometer, VISULENS® 500 auto-lensmeter and the 4-in-1 wavefront aberrometer i.Profiler plus.
With the Essential Line, ZEISS delivers a complete pre-test and basic diagnostics solution that assists ophthalmologists and optometrists in achieving optimal results and enhancing their workflow.
"Basic diagnostics is particularly important in the practices of ophthalmologists and optometrists. The very first examination of a new patient lays the foundation for the subsequent success of the therapy. Therefore, we wish to provide doctors with diagnostic solutions that deliver all important examination results reliably and efficiently," says Dr. Ludwin Monz, CEO of Carl Zeiss Meditec AG. He also highlighted the outstanding ease of use and modularity of the systems.
“Eye care providers can start with a single device and then gradually supplement it with additional equipment to create a complete suite", Dr. Monz said.
To guarantee smooth workflows, the devices of the Essential Line can be combined with each other and with already existing practice management systems (such as electronic medical records).
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2012/2013 (ended 30 September) the company's around 2,500 employees generated revenue of EUR 906 million. Carl Zeiss Meditec headquarters are located in Jena, Germany.
The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research in India (CARIn) in Bangalore, India, and the Carl Zeiss Innovation Center for Research and Development in Shanghai, China, strengthen the company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining 65% are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
In the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, Carl Zeiss has contributed to technological progress for more than 160 years and enhances the quality of life of many people around the globe. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.
For more information, please go to www.meditec.zeiss.com
